Drug dosage in isolated limb perfusion: evaluation of a limb volume model for extremity volume calculation

World Journal of Surgical Oncology

Georg Taeger²  Florian Grabellus¹  Lisa Dahlkamp⁴  Michael Herbrik⁵  Thorsten Poeppel³  Lars Erik Podleska⁴ 

[1] Institute of Pathology and Neuropathology, University Hospital of Essen and Sarcoma Center at the West German Cancer Center (WTZ), University of Duisburg-Essen, Essen, Germany;Department of Musculoskeletal Surgical Oncology, University Hospital of Essen and Sarcoma Center at the West German Cancer Center (WTZ), University of Duisburg-Essen, Essen, Germany;Department of Nuclear Medicine, University Hospital of Essen, University of Duisburg-Essen, Essen, Germany;Department of Trauma Surgery and Musculoskeletal Surgical Oncology, University Hospital of Essen and Sarcoma Center at the West German Cancer Center (WTZ), University of Duisburg-Essen, Hufelandstr. 55, D-45122 Essen, Germany;Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital of Essen, University of Duisburg-Essen, Essen, Germany

关键词: Drug dosage;    Isolated limb perfusion;    Regional perfusion;    Sarcoma;    Volumetry;    Melphalan;    TNF-alpha;   

Others  :  820081
DOI  :  10.1186/1477-7819-12-81

 received in 2013-05-05, accepted in 2014-03-16,  发布年份 2014

【 摘 要 】

Background

Exact drug dosing in isolated limb perfusion (ILP) and infusion (ILI) is essential. We developed and evaluated a model for calculating the volume of extremities and compared this model with body weight- and height-dependent parameters.

Methods

The extremity was modeled by a row of coupled truncated cones. The sizes of the truncated cone bases were derived from the circumference measurements of the extremity at predefined levels (5 cm). The resulting volumes were added. This extremity volume model was correlated to the computed tomography (CT) volume data of the extremity (total limb volume). The extremity volume was also correlated with the patient’s body weight, body mass index (BMI) and ideal body weight (IBW). The no-fat CT limb volume was correlated with the circumference-measured limb volume corrected by the ideal-body-weight to actual-body-weight ratio (IBW corrected-limb-volume).

Results

The correlation between the CT volume and the volume measured by the circumference was high and significant. There was no correlation between the limb volume and the bare body weight, BMI or IBW. The correlation between the no-fat CT volume and IBW-corrected limb volume was high and significant.

Conclusions

An appropriate drug dosing in ILP can be achieved by combining the limb volume with the simple circumference measurements and the IBW to body-weight ratio.

【 授权许可】

   
2014 Podleska et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Sparreboom A, Wolff AC, Mathijssen RH, Chatelut E, Rowinsky EK, Verweij J, Baker SD: Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. J Clin Oncol 2007, 25:4707-4713.
• [2]Pai MP: Drug dosing based on weight and body surface area: mathematical assumptions and limitations in obese adults. Pharmacotherapy 2012, 32:856-868.
• [3]Grabellus F, Kraft C, Sheu-Grabellus SY, Bauer S, Podleska LE, Lauenstein TC, Pottgen C, Konik MJ, Schmid KW, Taeger G: Tumor vascularization and histopathologic regression of soft tissue sarcomas treated with isolated limb perfusion with TNF-alpha and melphalan. J Surg Oncol 2011, 103:371-379.
• [4]Deroose JP, van Geel AN, Burger JW, Eggermont AM, Verhoef C: Isolated limb perfusion with TNF-alpha and melphalan for distal parts of the limb in soft tissue sarcoma patients. J Surg Oncol 2011, 105:563-569.
• [5]Deroose JP, Eggermont AM, van Geel AN, Burger JW, den Bakker MA, de Wilt JH, Verhoef C: Long-term results of tumor necrosis factor alpha- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas. J Clin Oncol 2011, 29:4036-4044.
• [6]Taeger G, Grabellus F, Podleska LE, Müller S, Ruchholtz S: Effectiveness of regional chemotherapy with TNF-alpha/melphalan in advanced soft tissue sarcoma of the extremities. Int J Hyperthermia 2008, 24:193-203.
• [7]Grunhagen DJ, de Wilt JH, Graveland WJ, Verhoef C, van Geel AN, Eggermont AM: Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma. Cancer 2006, 106:1776-1784.
• [8]Eggermont AM, Schraffordt Koops H, Klausner JM, Kroon BB, Schlag PM, Lienard D, van Geel AN, Hoekstra HJ, Meller I, Nieweg OE, Kettelhack C, Ben-Ari G, Pector JC, Lejeune FJ: Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 1996, 224:756-764. discussion 764–765
• [9]Deroose JP, Grunhagen DJ, van Geel AN, de Wilt JH, Eggermont AM, Verhoef C: Long-term outcome of isolated limb perfusion with tumour necrosis factor-alpha for patients with melanoma in-transit metastases. Br J Surg 2011, 98:1573-1580.
• [10]Deroose JP, Eggermont AM, van Geel AN, Verhoef C: Isolated limb perfusion for melanoma in-transit metastases: developments in recent years and the role of tumor necrosis factor alpha. Curr Opin Oncol 2011, 23:183-188.
• [11]Grunhagen DJ, de Wilt JH, van Geel AN, Eggermont AM: Isolated limb perfusion for melanoma patients–a review of its indications and the role of tumour necrosis factor-alpha. Eur J Surg Oncol 2006, 32:371-380.
• [12]Deroose JP, Eggermont AM, van Geel AN, de Wilt JH, Burger JW, Verhoef C: 20 years experience of TNF-based isolated limb perfusion for in-transit melanoma metastases: TNF dose matters. Ann Surg Oncol 2012, 19:627-635.
• [13]Duprat Neto JP, Oliveira F, Bertolli E, Molina AS, Nishinari K, Facure L, Fregnani JH: Isolated limb perfusion with hyperthermia and chemotherapy: predictive factors for regional toxicity. Clinics (Sao Paulo) 2012, 67:237-241.
• [14]Santillan AA, Delman KA, Beasley GM, Mosca PJ, Hochwald SN, Grobmyer SR, Andtbacka RH, Noyes RD, Kane JM, Ross MI, Tyler DS, Zager JS: Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysis. Ann Surg Oncol 2009, 16:2570-2578.
• [15]Grunhagen DJ, de Wilt JH, van Geel AN, Graveland WJ, Verhoef C, Eggermont AM: TNF dose reduction in isolated limb perfusion. Eur J Surg Oncol 2005, 31:1011-1019.
• [16]Wieberdink J, Benckhuysen C, Braat RP, van Slooten EA, Olthuis GA: Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982, 18:905-910.
• [17]van Os J, Schraffordt Koops H, Oldhoff J: Dosimetry of cytostatics in hyperthermic regional isolated perfusion. Cancer 1985, 55:698-701.
• [18]Byrne DS, McKay AJ, Blackie R, MacKie RM: A comparison of dosimetric methods in isolated limb perfusion with melphalan for malignant melanoma of the lower extremity. Eur J Cancer 2082–2087, 1996:32A.
• [19]McMahon N, Cheng TY, Beasley GM, Spasojevic I, Petros W, Augustine CK, Zipfel P, Padussis JC, Sanders G, Tyler DS: Optimizing melphalan pharmacokinetics in regional melanoma therapy: does correcting for ideal body weight alter regional response or toxicity? Ann Surg Oncol 2009, 16:953-961.
• [20]Huismans AM, Kroon HM, Haydu LE, Kam PC, Thompson JF: Is melphalan dose adjustment according to ideal body weight useful in isolated limb infusion for melanoma? Ann Surg Oncol 2012, 19:3050-3056.
• [21]Kam PC, Thompson JF: Isolated limb infusion with melphalan and actinomycin D in melanoma patients: factors predictive of acute regional toxicity. Expert Opin Drug Metab Toxicol 2010, 6:1039-1045.
• [22]Heymsfield SB, Fulenwider T, Nordlinger B, Barlow R, Sones P, Kutner M: Accurate measurement of liver, kidney, and spleen volume and mass by computerized axial tomography. Ann Intern Med 1979, 90:185-187.
• [23]Luciani A, Rusko L, Baranes L, Pichon E, Loze B, Deux JF, Laurent A, Tran-Van-Nhieu J, Rahmouni A: Automated liver volumetry in orthotopic liver transplantation using multiphase acquisitions on MDCT. AJR Am J Roentgenol 2012, 198:W568-W574.
• [24]Gao L, Heath DG, Kuszyk BS, Fishman EK: Automatic liver segmentation technique for three-dimensional visualization of CT data. Radiology 1996, 201:359-364.
• [25]Frericks BB, Caldarone FC, Nashan B, Savellano DH, Stamm G, Kirchhoff TD, Shin HO, Schenk A, Selle D, Spindler W, Klempnauer J, Peitgen HO, Galanski M: 3D CT modeling of hepatic vessel architecture and volume calculation in living donated liver transplantation. Eur Radiol 2004, 14:326-333.
• [26]Eggermont AM, Schraffordt Koops H, Lienard D, Kroon BB, van Geel AN, Hoekstra HJ, Lejeune FJ: Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol 1996, 14:2653-2665.
• [27]Grabellus F, Kraft C, Sheu SY, Ebeling P, Bauer S, Lendemans S, Schmid KW, Taeger G: Evaluation of 47 soft tissue sarcoma resection specimens after isolated limb perfusion with TNF-alpha and melphalan: histologically characterized improved margins correlate with absence of recurrences. Ann Surg Oncol 2009, 16:676-686.
• [28]Extremity volume calculation tool http://www.uk-essen.de/published/ilp-volume-calc-tool webcite
• [29]Beasley GM, Petersen RP, Yoo J, McMahon N, Aloia T, Petros W, Sanders G, Cheng TY, Pruitt SK, Seigler H, Tyler DS: Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann Surg Oncol 2008, 15:2195-2205.
• [30]Kroon HM, Moncrieff M, Kam PC, Thompson JF: Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients. Ann Surg Oncol 2009, 16:1184-1192.